Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 4/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888859 | 0.84 | HTR2B (0.60) | HTR2BHRH1CHRNA7PKM | |
| SCHEMBL17888847 | 0.84 | HTR2B (0.55) | HTR2BHRH1CHRNA7POLBMAPT | |
| SCHEMBL17888861 | 0.84 | HTR2B (0.62) | HTR2BCHRNA7PKM | |
| SCHEMBL17888844 | 0.83 | HTR2B (0.59) | HTR2BHRH1CHRNA7PKMPOLB | |
| SCHEMBL17888851 | 0.82 | HRH1 (0.58) | HTR2BHRH1PKMPOLBMAPT | |
| SCHEMBL7533221 | 0.80 | HTR2B (0.60) | HTR2BCHRNA7PKM | |
| SCHEMBL14218700 | 0.76 | HTR2B (0.65) | HTR2BCHRNA7PKMPOLBMAPT | |
| SCHEMBL7501230 | 0.75 | HTR2B (0.61) | HTR2BCHRNA7PKM | |
| SCHEMBL6883705 | 0.75 | PKM (0.62) | HTR2BPKM | |
| SCHEMBL9870915 | 0.74 | HTR2B (0.56) | HTR2BCHRNA7PKMPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016251-A1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | FAES FARMA, S.A. (ES) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016251-A1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | HRH2, HRH4, HRH1 | HTR2B 231/4885HRH1 3/4885CHRNA7 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.